Insmed's stock price surged 5.05% during intraday trading on Monday, reflecting significant positive investor sentiment.

The sharp increase follows a recent analyst note from Stifel Nicolaus, where analyst Stephen Willey maintained a Buy rating on the company and set a price target of $200.00. This reaffirmation of confidence from a major financial institution is likely driving the current buying pressure.